WhatsApp
backNews Article

Lupin Limited's Biosimilar Ranibizumab RanluspecTM Launches Across Europe Excluding Germany After European Commission Approval

Following regulatory approval, Lupin and Sandoz introduce RanluspecTM in vial and pre-filled syringe forms to treat multiple retinal vascular diseases

Lupin Limited, through commercial partner Sandoz, launched RanluspecTM, its biosimilar Ranibizumab, throughout Europe except Germany following European Commission approval. RanluspecTM is indicated for treatment of retinal diseases including wet age-related macular degeneration and diabetic macular edema, marking a significant step in expanding access to biologic treatments for these conditions.

7 days ago|LUPIN-0.54%
Lupin LimitedLUPINNew Ventures

Lupin Limited

New Ventures

Lupin Limited announced the launch of RanluspecTM, its biosimilar Ranibizumab, across Europe excluding Germany via its commercial partner Sandoz, following European Commission approval. This launch aims to expand access to biologic treatments for retinal diseases.

RanluspecTM, a recombinant humanized IgG1 monoclonal antibody fragment targeting vascular endothelial growth factor A, is available in vial and pre-filled syringe presentations.

The biosimilar is approved for treating neovascular (wet) age-related macular degeneration, macular edema from retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.

Lupin’s leadership highlighted that the launch is part of their strategy to broaden patient access to high-quality biosimilars for retinal and choroidal vascular diseases across Europe.

The launch also underscores Lupin’s biosimilar scientific and manufacturing capabilities and their commitment to supporting healthcare system sustainability.

Highlights

  • RanluspecTM launched across Europe excluding Germany.
  • Approved indications include wet age-related macular degeneration and diabetic macular edema among others.
  • Available in vial and pre-filled syringe forms.
  • Launch executed through Lupin’s partner Sandoz.
  • The product received European Commission approval prior to launch.

Key Data Snapshot

Product nameRanluspecTM
Active ingredientBiosimilar Ranibizumab
Commercial partnerSandoz
Launch geographyEurope excluding Germany
Approval authorityEuropean Commission
Presentation formsVial and pre-filled syringe
Approval datePrior to November 12, 2026
Treatment indicationsNeovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, choroidal neovascularization

What happened

  • Lupin Limited’s biosimilar Ranibizumab, RanluspecTM, has been launched across Europe, excluding Germany.
  • The launch follows approval by the European Commission.
  • Commercial partner Sandoz is responsible for the product launch and distribution.

Key details

  • RanluspecTM is available in vial and pre-filled syringe presentations.
  • It treats a range of retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema.
  • The biosimilar acts by inhibiting vascular endothelial growth factor A, a key driver in retinal disease progression.

Strategic context

  • The launch aligns with Lupin’s strategy to increase access to high-quality biosimilars in retinal and choroidal vascular diseases.
  • This initiative highlights Lupin’s scientific expertise and manufacturing capabilities in biologics.
  • Lupin aims to support more sustainable healthcare systems by expanding biosimilar availability.

Background and context

  • Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets.
  • The company develops branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
  • Lupin has over 26,000 professionals working across 15 manufacturing sites and 6 research centers globally.

More News on New Ventures

View all

Latest corporate announcements and market updates in New Ventures.

View all news
Lupin Limited's Biosimilar Ranibizumab RanluspecTM | Stockk News